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Summary
Anti-virulence (AV) compounds are a promising alter-
native to traditional antibiotics for fighting bacterial
infections. The Type Three Secretion System (T3SS)
is a well-studied and attractive AV target, given that it
is widespread in more than 25 species of Gram-
negative bacteria, including enterohemorrhagic E.
coli (EHEC), and as it is essential for host coloniza-
tion by many pathogens. In this work, we designed,
synthesized and tested a new series of compounds
that block the functionality of the T3SS of EHEC.
Affinity chromatography experiments identified the
primary target of the compounds as the T3SS needle
pore protein EspD, which is essential for effector pro-
tein translocation into host cells. These data were
supported by mechanistic studies that determined
the coiled-coil domain 1 of EspD as a key compound-
binding site, thereby preventing correct assembly of
the T3SS complex on the cell surface. However, bind-
ing of inhibitors to EspD or deletion of EspD itself did
not result in transcriptional down-regulation of effec-
tor proteins. Instead, we found the compounds to
exhibit dual-functionality by also down-regulating
transcription of the entire chromosomal locus encod-
ing the T3SS, further demonstrating their desirability
and effectiveness.
Introduction
Antibiotic resistance is increasing among common bac-
terial pathogens and is now considered a global threat
by the World Health Organization (http://www.who.int/en/).
Anti-virulence (AV) therapies are a promising alternative
to traditional antibiotics for fighting bacterial infections. A
key feature of this strategy is that ‘virulence-blocking’
mechanisms designed to target only the functionality of
virulence factors carried by pathogens. This specificity
helps avoid effects on the endogenous microflora and
thereby exerts less selective pressure, reducing the devel-
opment of resistance (Rasko and Sperandio, 2010; Beck-
ham and Roe, 2014; Allen et al., 2014). One potential
target for AV therapy is the bacterial type three secretion
system (T3SS), a conserved protein injection organelle
that is central to the virulence of over 25 species of
human, animal, and plant pathogens including enteropa-
thogenic and enterohemorrhagic E. coli (EHEC), Chla-
mydia spp, Pseudomonas aeruginosa, Salmonella spp.,
Shigella spp., Citrobacter rodentium and Yersinia spp.
(Cornelis, 2006; Keyser et al., 2008; B€uttner, 2012; Collins
et al., 2014). The T3SS is a complex needle-like structure
that penetrates the host cell membrane and functions as
a conduit to translocate virulence effectors, intimately
attach and ultimately creating a niche to allow the patho-
gen to survive (Cornelis, 2006; B€uttner, 2012).
Colonization of both humans and animals by EHEC is
highly dependent on its T3SS, encoded on a large hori-
zontally acquired pathogenicity island, which enables inti-
mate adhesion to and subversion of host epithelial
intestinal cells. A key feature of this process is the devel-
opment of attaching and effacing (A/E) lesions on the
host cell membrane, defined by pedestal-like cytoskeletal
rearrangements induced by T3SS effector proteins
(Moon et al., 1983; McDaniel et al., 1995; Nataro and
Kaper, 1998; Frankel et al., 1998; Wong et al., 2011).
The expression, regulation and function of the T3SS is
complex and has been researched and reviewed exten-
sively (Cornelis, 2006; Mellies et al., 2007; B€uttner,
2012; Connolly et al., 2015). Three T3SS components
most relevant to this study are EspA, EspD and Tir. The
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needle-like structure that spans the bacterial membrane
and allows effector proteins to be delivered into host
cells is assembled by the polymerization of EspA (Knut-
ton et al., 1998; Yip et al., 2005). The EspA needle is
then capped by EspD, a 39 kDa protein predicted to
comprise of two coiled-coil domains for host cell mem-
brane anchoring and homo-oligomerization, two trans-
membrane domains for insertion and two amphipathic
regions involved in chaperone recognition (Daniell et al.,
2001; Dasanayake et al., 2011). EspD subunits insert
into the host cell membrane creating a translocation-pore
allowing the injection of a suite of effector proteins into
the host cell milieu (Shaw et al., 2001; Chatterjee et al.,
2015). Arguably the most important of these effectors is
Tir, which is integrated into the membrane of the host
cell following its translocation into the host cell cytosol.
Tir serves as a receptor for intimin (Translocated intimin
receptor) and the interaction between these two compo-
nents initiates reorganization of the host cell cytoskeleton
and intimate attachment (Kenny et al., 1997).
A well studied class of AV compounds, the salicylidene
acylhydrazides (SAs), were originally identified as putative
T3SS inhibitors in Yersinia pseudotuberculosis (Kauppi
et al., 2003; Nordfelth et al., 2005). The compounds were
shown to be broadly effective in inhibiting the function of
the T3SS in a number of pathogenic bacteria including
Chlamydia spp., Salmonella typhimurium, Shigella spp.
and EHEC (Muschiol et al., 2006; Bailey et al., 2007;
Hudson et al., 2007; Tree et al., 2009; Veenendaal et al.,
2009). To help understand the molecular mechanism by
which the SAs affect the T3SS, we previously identified
the cellular targets for this group of compounds and
showed that their mode of action likely results from a syn-
ergistic effect arising from a perturbation of the function of
several conserved metabolic proteins (Wang et al., 2011).
We concluded that although effective, the SAs were rather
promiscuous. The compounds also displayed poor solubil-
ity in biological buffers and proved to be prone to hydroly-
sis in acidic aqueous conditions. Therefore, the aim of our
study was to try and develop novel compounds with better
stability and selectivity. Accordingly, we have identified a
new class of AV compounds capable of inhibiting the
T3SS in a highly selective manner. We have demon-
strated that the translocation pore protein EspD acts as
the primary target for these compounds resulting in inhibi-
tion of effector secretion and that unlike their counterpart
SA compounds, there is no detrimental effects on bacte-
rial growth or viability thus fulfilling one of the key criteria
of AV therapy. This comprehensive analysis provides a
baseline for future work and development of this effective
class of T3SS inhibitor compounds.
Results
Synthesis of new SA derivative compounds
We have previously demonstrated that the salicylidene
acylhydrazide compound ME0055 is a potent inhibitor of
the T3SS of EHEC (Tree et al., 2009; Wang et al., 2011).
However, although effective, the compound was shown to
be rather promiscuous, interacting with several bacterial
proteins. Moreover, ME055 is poorly soluble in biological
buffers and is prone to hydrolysis in acidic aqueous con-
ditions. Therefore, it was decided to modify the ME0055
structure by incorporation of the imine moiety into two dif-
ferent hydrazine-containing heterocycles, 1,4,5,6-tetrahy-
dropyridazine (THP) and 1,2-dihydrophthalazine (DHP)
(Fig. 1). Key substituents on both phenyl rings were
Fig. 1. Overview of the series of compounds generated in this study. The imine motif of ME0055 was stabilized in two hydrazine-containing
heterocycles: 1,4,5,6-tetrahydro-pyridazine and 1,2-dihydro-phthalazine (THP and DHP). Around this core, both carbonyl and sulfonyl groups
were incorporated to provide diversity. Similarly, methyl substitutions of the hydroxyl groups on the THP and DHP cores were generated.
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retained for a direct comparison with ME0055. The syn-
thesis of our derivatives (see Supporting Information
Materials and Methods) started from resorcindimethy-
lether (1), which underwent Friedel-Crafts acylation with
both succinic or phthalic anhydrides to afford carboxylic
acids intermediates 2 and 3. Pyridazinone 4 and phthala-
zinone 5 were obtained in excellent yield by treating 2
and 3 with hydrazine hydrate in refluxing ethanol. Lithium
aluminum hydride reduction afforded the corresponding
amines 6 and 7. Acylation with 4-nitrobenzoyl chloride
subsequently achieved the di-methoxy analogues RCZ09
(THP) and RCZ17 (DHP) in moderate yield. After trying
different demethylation conditions, we obtained the di-
hydroxyl derivatives RCZ10 (THP) and RCZ18 (DHP)
with boron tribromide at 408C. A sulfonyl version of both
the THP and DHP derivatives was also synthesized to
expand the series. Amines 6 and 7, were consequently
sulfonylated with nosyl chloride to achieve the corre-
sponding dimethoxy-sulfonyl analogues RCZ11 (THP)
and RCZ19 (DHP). Demethylation was performed follow-
ing the previous conditions to afford the sulfonyl di-
hydroxyl molecules RCZ12 (THP) and RCZ20 (DHP).
Schematic synthesis maps can be seen in Supporting
Information Fig. S1.
Biological evaluation of the novel AV compounds
ME0055 has previously been evaluated for activity
against the T3SS of EHEC (Tree et al., 2009; Wang
et al., 2011). Eight new compounds were generated for
biological testing against EHEC: the two carbonyl di-
hydroxyl THP and DHP compounds, RCZ10 and
RCZ18, with their corresponding carbonyl di-methoxy
counterpart, RCZ09 and RCZ17, and the two sulfonyl
di-hydroxyl analogues, RCZ12 and RCZ20, with the sul-
fonyl di-methoxy counterpart, RCZ11 and RCZ19 (Fig.
1). We screened the new compounds ability to block
T3SS-mediated protein secretion (using the secreted
protein EspD as a probe), similarly to ME0055 (Fig. 2A).
As expected, ME0055 showed a strong fivefold reduc-
tion of the protein secretion at 50 lM. Reduced secre-
tion was also detected for our new candidates. Carbonyl
di-methoxy analogues (RCZ09 and RCZ17) did not
reduce EspD secretion in a significant way, while the
sulfonyl di-methoxy molecules (RCZ11 and RCZ19) had
a slightly stronger effect than the carbonyl counterpart,
decreasing of twofold the relative secretion of the pro-
tein (Fig. 2A). The same pattern was detected for the
four di-hydroxyl compounds (RCZ10, 12, 18 and 20)
with the sulfonyl di-hydroxyl derivatives (RCZ12 and
RCZ20) having a stronger inhibition profile than the car-
bonyl counterparts (RCZ10 and RCZ18). RCZ12 and
RCZ20 displayed the most promising activity against
EspD secretion, displaying a fourfold reduction in rela-
tive secretion (Fig. 2A). It was interesting to note that
inhibition by the four di-hydroxyl derivatives was gener-
ally more marked than the four di-methoxy molecules,
suggesting that the hydroxyl groups may be essential
for activity. The effect exhibited by RCZ12 and RCZ20
was comparable to ME0055 activity and thus these two
compounds were carried forward for further evaluation.
Since we were testing new potential AV compounds,
which should target only virulence factors (Allen et al.,
2014), the bacterial growth in presence of our new can-
didates was evaluated at a concentration of 100 lM
(Fig. 2B). Optical density (OD600) of bacteria grown in
T3SS-inducing media (MEM-HEPES) was measured
hourly. ME0055 was demonstrated to have a measura-
ble effect the growth rate at this concentration, as previ-
ously reported (Tree et al., 2009), whereas the new
THP and DHP derivatives did not affect bacterial growth.
Furthermore, we tested the viability of bacteria grown in
high concentrations of our compounds by colony count
analysis. Encouragingly, the RCZ compounds did not
affect the bacterial viability even at 200 lM. Targeted
metabolomic analysis of whole cell lysates and superna-
tants also confirmed the uptake of our compounds into
the bacterial cytosol, eliminating any concerns about
compound suitability. The signal intensity of RCZ12/20
from the bacterial cytosolic fraction was approximately
9.2- and 9.5-fold (log2) higher than that detectable in the
supernatant respectively (Supporting Information Fig.
S2). These results provide further evidence for the suit-
ability of our compounds as AV inhibitor candidates. A
further desirable property of the compounds is better
stability in acidic conditions. Incubation of ME055 in
20% HCl and 1H NMR analysis over a time course indi-
cated hydrolysis within 2 h with the appearance of the
aldehyde peak at 9.2 ppm corresponding to the 2,4-
dihydroybenzaldehyde and disappearance of the imine
hydrogen at 8.7 ppm (Supporting Information Fig. S3A–
C). In contrast RCZ12 showed no evidence of hydrolysis
in the presence of acid over the 12 h time course tested
(Supporting Information Fig. S3D and E).
We next began to explore the mode of action of the
new compounds. First, we evaluated the efficacy of
RCZ12 and RCZ20 across a range of concentrations
from 10 to 200 lM (Fig. 2C). The repression of EspD
secretion was concentration dependent, with measura-
ble inhibition appearing at 25 lM and increasing with
the concentration gradient, greater than fivefold at 200
lM. Second, we performed immunoblot analysis on
secreted protein fractions for a second secreted protein,
Tir. Similarly to EspD, Tir secretion was undetectable
when grown in the presence of either RCZ12 or RCZ20
at 200 lM (Fig. 2D). To address whether these results
indicate inhibition of protein secretion or an actual
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Fig. 2. Biological evaluation of novel T3SS inhibitor compounds.
A. Total secreted protein levels were assayed in cultures of EHEC grown in MEM-HEPES with or without the series of novel compounds (100
lM) and probed for relative EspD levels by immunoblot. The data are represented as a percentage of total EspD secreted in the wild type
(WT) background. ME0055 was used as a positive control for secretion inhibition. Samples were normalized according to the OD600 of the
culture and the equal addition of exogenous BSA was used as a loading control.
B. Growth curves of EHEC cultured in MEM-HEPES supplemented with the novel derivatives described in panel A. DMSO was used as a
control given its use as the compound solvent.
C. Concentration dependent inhibition of type 3 secretion by RCZ12/20. Immunoblot analysis of secreted EspD levels after treatment of
bacterial cultures with 10–200 lM of RCZ12/20.
D. Comparative analysis of EspD and Tir secretion as well as expression in whole cell lysates from cell cultures treated with 200 lM of
RCZ12/20. The secreted supernatant (S/N) and whole cell lysate (W/C) are labeled accordingly. Levels of GroEL and exogenous BSA were
probed in the W/C and S/N fractions respectively to assess equal protein loading.
E. Scanning electron microscopy (SEM) analysis of T3SS formation on WT cells and after treatment with RCZ12/20. Cultures were fixed for
SEM and gold-immunolabeling of EspA was performed to visualize T3SS filament formation (black arrows). The DespD mutant strain was
used as a control. All experiments described were performed at least in biological triplicate.
F. Enumeration of EspA filament number per cell and filament length (lm) of EHEC cells before and after treatment with RCZ12/20 as shown
in panel E.
New compounds targeting E. coli T3SS 609
VC 2017 The Authors. Molecular Microbiology Published by John Wiley & Sons Ltd., Molecular Microbiology, 105, 606–619
inhibition of Tir/EspD production we also probed the
whole cell lysate with EspD and Tir antibodies. Intrigu-
ingly, EspD was found to accumulate inside the cells
despite inhibition of secretion whereas Tir production
was actually decreased in whole cell lysates (Fig. 2D).
This is contrast to ME0055, which inhibits both produc-
tion and secretion of EspD and thus suggests a distinct
mode of action. Total protein loading levels were normal-
ized by probing for the non-virulence, heat shock pro-
tein, GroEL, which was unaffected by the compounds.
These results indicated that our new derivatives likely
act in a different manner to the SA compound. While
ME0055 activity seemed to be blocking the T3SS appa-
ratus at transcriptional level, both RCZ12 and RCZ20
mode of action seemed to be more focused on nega-
tively affecting the ability of T3SS to translocate effector
proteins such as EspD and Tir.
Immunoblot analyses suggested that blocking protein
secretion rather than production may be mediating
T3SS repression exhibited by our new compounds.
Indeed, we see little affect on the intracellular produc-
tion of EspD but protein secretion remains inhibited.
We reasoned that this could be due to a post-
transcriptional mechanism. Indeed, expression of EspD
is known to be essential for the formation of T3SS fila-
ment structures on the bacterial cell surface (Kresse
et al., 1999). Therefore, we investigated this by way of
scanning electron microscopy. Wild type EHEC pro-
duced an average of 8 long EspA needle formations
(1000 nm) per bacterium, while a DespD mutant did
not produce extended needle structures (Fig. 2E).
RCZ12 and RCZ20 treated bacteria similarly had fewer
characteristic T3SS needles on their cell surface (Fig.
2E) with an average of 1–2 needles per bacterium (Fig.
2F). These cells were comprised of shorter needles
than that of the wild type, averaging in 200 nm in
length (Fig. 2F). Furthermore, there was an apparent
accumulation of EspA at the cell surface of RCZ12/20
treated bacteria, which suggests an aborted T3SS
apparatus (Fig. 2E).
Identification of RCZ12/20 cellular targets
Phenotypic evaluation of compounds RCZ12 and
RCZ20 suggested inhibition of the T3SS by interference
of needle assembly and protein secretion. To determine
how this inhibition was taking place we performed whole
cell lysate pull-down experiments using biotinylated
derivatives of RCZ12/20. We reasoned that since a
reduction of EspD secretion was detected with the sul-
fonyl di-methoxy analogues in our preliminary assays,
the two hydroxyl groups on the right-hand side of the
molecule may be essential for the interaction. We
therefore chose to insert the biotin tag on the left-hand
side of our candidates.
The synthesis of biotinylated RCZ12/20 (Supporting
Information Materials and Methods) began as treatment
with allyl bromide to generate intermediates 8 and 9 in
excellent yields. Nitro reduction was carried out in mild
conditions in the presence of iron and an aqueous solu-
tion of NH4Cl in refluxing ethanol. Intermediates 10 and
11 underwent acylation with hex-5-ynoyl chloride to
obtain both alkyne intermediates 12 and 13. Huisgen
copper catalyzed 1,3-dipolar cycloaddition between the
alkyne intermediates, 12 and 13, and biotin-N3 was per-
formed in presence of copper(II)sulfate and sodium
ascorbate in a 3:1 mixture of THF and water at 508C
(31). The protected biotin-labeled RCZ12 and RCZ20
products 14 and 15 were de-protected with tetrakis(tri-
phenylphosphine)palladium in refluxing methanol (32),
thus resulting in biotin-RCZ12 and biotin-RCZ20 synthe-
sized in 5 steps. Schematic synthesis maps can be
seen in Supporting Information Fig. S4.
Streptavidin-coated magnetic beads were utilized to
perform the pull-down assay with our two biotinylated
compounds, due to the high affinity between biotin and
streptavidin. The beads were firstly incubated with the
biotin derivatives and then with EHEC whole cell lysate
from cells cultured in MEM-HEPES. The beads were
washed to remove nonspecifically bound protein and
boiled in SDS to denature the bound protein. Boiled pro-
tein samples bound to biotinylated RCZ12/20 were sep-
arated and visualized by SDS-PAGE followed by tandem
mass spectrometry analysis for identification (Fig. 3A).
The magnetic beads were also incubated with the whole
cell lysate from cells cultured without biotinylated
RCZ12/20 as a control for nonspecific interactions (Fig.
3A). Biotin-RCZ12 and biotin-RCZ20 (Fig. 3B) were
found to have an almost identical banding pattern indi-
cating affinity for similar proteins and likely the same
cellular targets (Fig. 3C). Interestingly, the most abun-
dant band identified in the assay corresponded to EspD
(MOWSE score/# peptides matched: 1266/45 for RCZ12
and 1174/40 for RCZ20), along with 2-oxoglutarate
dehydrogenase (1716/106) and elongation factor Tu (Ef-
Tu) (745/75) (Fig. 3C). Both the 2-oxoglutarate-
dehydrogenase and Ef-Tu were considered as ‘off-
target’ proteins as they are not directly involved in the
EspD secretion process or T3SS assembly. An addi-
tional band identified corresponded to 30S ribosomal
subunit S10 (235/10) but this was demonstrated to be a
nonspecific interaction bound to streptavidin rather than
our biotinylated compounds, as indicated in the negative
control samples. Thus EspD appeared to be the only
genuine T3SS-related target that showed affinity for
both our biotinylated compounds. These results suggest
that the cellular target of RCZ12/20 is the translocation
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pore protein EspD and that this interaction could explain
the inhibition of protein secretion and EspA needle for-
mation without any effects on EspD production. Further-
more, the target identification of our new compounds
shows a drastic improvement in selectivity over the pre-
vious SA compound ME0055, which reacted with 14 cel-
lular targets in a pull-down assay, none of which were
T3SS related proteins (Wang et al., 2011).
Analysis of EspD as a cellular target of the T3SS
inhibitors RCZ12/12
Currently no structural data exists for EspD making pre-
dictions as to the likely binding site problematic. To over-
come this, we used a genetic approach to mutate
functional domains of EspD (Fig. 4A) and investigate
activity with RCZ12/20. Mutant strains of EHEC contain-
ing truncated EspD coding regions, each tagged with
the HA epitope to allow probing by western blot, were
generated by allelic exchange. A total of 5 mutants were
generated. First, we created a full-length EspD-HA
strain. Next, we sequentially deleted 4 essential regions
of the protein coding sequence – the 2 amphipathic
regions (EspD-HAD26–81), the coiled-coil domain 1
(EspD-HAD138–171), the 2 transmembrane domains
(EspD-HAD176–251) and the coiled-coil domain 2 (EspD-
HAD333–356). We assessed the ability of our mutant
strains to express and secrete the modified EspD-HA
derivatives. The mutant strains were cultured in MEM-
HEPES and both the supernatant and whole cell lysate
were analyzed by western blot (Fig. 4B). All EspD-HA
derivatives except for EspD-HAD26–81 were detectable in
both cellular fractions. As previously observed, deletion
of the 2 amphipathic regions generated an unstable con-
struct (EspD-HAD26–81), which cannot be recognized by
its chaperone and is rapidly degraded (Dasanayake
et al., 2011). These data demonstrate that four of our
mutant strains can produce detectable EspD truncates
that are capable of being secreted.
Next, we assessed the ability of our compound
RCZ12 to inhibit protein secretion of the truncated EspD
mutant forms. The C-terminus tagged EspD-HA did not
result in any reduced inhibition as RCZ12 totally inhib-
ited EspD-HA secretion at 200 lM, as seen in the WT
protein (Fig. 4C). Conversely, a complete loss of activity
was detected for EspD-HAD138–171, while retention of
activity was observed for both EspD-HAD176–251 and
EspD-HAD333–356 (Fig. 4C). These results strongly sup-
port the notion that the EspD coiled-coil domain 1 acts
as an interacting partner of RCZ12/20, thus confirming
our hypothesis of an inhibitory interaction between our
Fig. 3. Biotin-Streptavidin affinity pulldown assay of RCZ12/20 with whole cell lysate of EHEC.
A. Coomassie stained SDS-PAGE gel of biotin-RCZ12/20 bound proteins. Each wash and elution stage is indicated above each well. The
negative control for nonspecific binding corresponds to the assay performed using Streptavidin beads alone. The experiment was performed in
triplicate.
B. The chemical structure of the biotin labeled RCZ12 and RCZ20 compounds used in the pull-down assays.
C. Table of results highlighting the targets of RCZ12/20 as identified by tandem mass spectrometry. The band number, genBank/protein ID,
MOWSE score and gene name are indicated.
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compounds and EspD. We can therefore postulate that
RCZ12/20 accumulate in E. coli and subsequently bind
to intracellular EspD, inducing a conformational change
that blocks the translocation of this protein and inhibits
T3SS pore formation.
Transcriptional effects induced by RCZ12/20 treatment
of EHEC
The data presented suggests that our newly designed
T3SS inhibitors RCZ12/20 function by binding EspD
inside the bacterial cell, interfering with functionality of
the translocation pore and thus inhibiting effector protein
secretion. However, studies thus far have focused on
RCZ12/20 binding to EspD and have not addressed the
effects of these compounds on the transcription of
virulence-associated genes. Despite an accumulation of
cellular EspD after compound treatment we observed
decreased expression of Tir. This can be explained by
one of two scenarios – either physical interference with
EspD causes a negative transcriptional feedback to
T3SS encoding genes or the compounds themselves
also act at the level of transcription regulation. The latter
was a characteristic of the original SA compounds and
thus was also investigated (Tree et al., 2009).
We investigated these hypotheses by applying RNA-
sequencing (RNA-seq) analysis to mRNA samples puri-
fied from cultures of EHEC grown in MEM-HEPES with
or without RCZ20. This gave us a ‘global’ high-
resolution view of the bacterial transcriptomes under
T3SS inducing conditions and in response to the novel
inhibitors. Figure 5A shows that RCZ20 treatment
resulted in differential expression of only 87 genes (FDR
p<0.05; Supporting Information Table S4). All the
genes necessary for the formation of a fully functional
T3SS are encoded on a 5 operon, polycistronic patho-
genicity island named the locus of enterocyte efface-
ment (LEE), which contains 41 open reading frames
(ORFs) (McDaniel et al., 1995; Elliott et al., 1998). Strik-
ingly, all 41 ORFs of the LEE were significantly down-
regulated after RCZ20 treatment, suggesting the com-
pounds have some effect on global regulation of this
pathogenicity island (Fig. 5B). Indeed, the ‘master regu-
lators’ of the LEE, Ler and GrlRA, that control transcrip-
tion of all 5 LEE operons are encoded within the island
Fig. 4. Identification of AV compound binding sites to EspD.
A. Schematic representation of the HA-tagged EspD peptide sequence from EHEC highlighting the relevant functional domains – the
amphipathic 1 and 2 regions (amino acids 26–81), the coiled-coil domain 1 (amino acids 138–171), the transmembrane domains 1 and 2
(amino acids 176–251), the coiled-coil domain 2 (amino acids 333–356) and the HA tag. A full length EspD-HA derivative was generated as
well as HA-tagged truncations in each of the above functional domains.
B. Immunoblot analysis of EspD-HA derivative expression and secretion. EHEC whole cell lysates (W/C) and secreted protein from
supernatants (S/N) were probed with anti-HA antibody. The shift in molecular weight due to truncations can be seen clearly when compared to
the full length EspD-HA. Anti-GroEL levels were probed from the W/C fraction to normalize protein loading.
C. Identification of an RCZ12 EspD inhibition site. Immunoblot analysis of EspD-HA levels in S/N fractions from EHEC cells cultured with (1)
and without (–) 200 lM RCZ12 in MEM-HEPES. The effects of RCZ12 treatment on EspD-HA derivative secretion were compared to the full
length EspD-HA, which was inhibited fully in a similar manner to WT EspD. Immunoblot experiments were all performed in triplicate.
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itself (Mellies et al., 1999; Sanchez-SanMartın et al.,
2001; Haack et al., 2003; Deng et al., 2004). Three other
transcriptional regulators were differentially expressed in
the data set – the phosphorelay response regulator rcsA,
the acid response regulator yhiW and the biofilm regula-
tor bssR. The Rcs phosphorelay and GAD acid response
systems have previously been linked to LEE regulation
but YhiW and RcsA were not found to be involved (Tat-
suno et al., 2003; Tobe et al., 2005; Tree et al., 2011).
rcsA is, however, known to be activated by Ler, therefore
explaining downregulation of this gene (Bingle et al.,
2014). In addition to transcriptional regulation and viru-
lence there were numerous genes affected by RCZ20.
However, functional classification of these genes failed to
identify any particularly enriched roles of the affected
genes. These included genes involved in processes such
as general metabolism, membrane structure and trans-
port or stress responses but the number of genes
affected were low in each category suggesting either indi-
rect or off target effects. Interestingly, the most enriched
gene categories outside of the LEE were hypothetical
genes (13 genes differentially expressed). Taken together
these results indicate that RCZ20 treatment indeed
results in transcriptional downregulation of the T3SS as
well as differential regulation of other genes. However,
the focus of the genes affected toward the LEE further
the highlights the powerful selectivity of our compounds.
RCZ12/20 exhibit dual functionality at the transcriptional
and post-transcriptional levels
The results of the RNA-seq and EspD-HA inhibition
experiments seemed somewhat paradoxical. The result
suggest two likely scenarios that can explain the find-
ings – either physical inhibition RCZ12/20 with EspD
leads to negative transcriptional feedback to the LEE or
RCZ12/20 exhibit dual-functionality as inhibitors. Deng
et al. previously analyzed the effects of systematically
deleting every ORF within the LEE of the murine patho-
gen Citrobacter rodentium (Deng et al., 2004). The
study found that deletion of espD had no apparent feed-
back on regulation of the LEE or protein secretion,
despite its essential role in type 3 secretion. To verify
that deletion of espD does not affect LEE regulation in
an EHEC background we constructed a DespD mutant
strain of TUV 93–0 and employed a set of previously
developed GFP-reporters plasmids (prpsM:GFP and
pLEE1:GFP) (Roe et al., 2003). These comprise the
promoters for either the small ribosomal protein (RpsM)
or the master regulator of the LEE (Ler) fused to GFP.
Analysis of prpsM:GFP activity in response to 50 and
200 lM RCZ12/20 and ME0055 confirmed that our com-
pounds have no apparent detrimental effects on
housekeeping gene expression unlike the previous SA
compound, ME055 (Fig. 5C). Furthermore, analysis of
pLEE1:GFP activity demonstrated that both RCZ12/20
and ME0055 treatment resulted in significant down-
regulation of the LEE1 promoter (Fig. 5C). These results
both confirm effectiveness of RCZ12/20 as T3SS inhibi-
tors and also validate the RNA-seq results described
above.
To address the question of EspD feedback on the
LEE we analyzed pLEE1:GFP activity in a DespD back-
ground. LEE1 transcription was unaffected by deletion
of espD (Fig. 5D). Strikingly, addition of RCZ12 to the
DespD strain resulted in a significant decrease in
pLEE1:GFP activity (Fig. 5D) indicating that irrespective
of the absence of the target EspD, RCZ12 is still capa-
ble of transcriptional repression of the LEE, supporting
the notion of RCZ12/20 dual-functionality. The EspD-HA
inhibition experiments identified the EspD coiled-coil
domain 1 as the likely target of RCZ12/20 binding to
this protein. To confirm that deletion of EspD did not
result in artifactual results we performed the pLEE1:GFP
activity analyses in an EspD-HAD138–171 background.
The results showed that modification of the coiled-coil
domain 1 did not affect LEE1 transcription, however,
treatment of this strain with RCZ12 indeed resulted in
significant LEE1 down-regulation (Fig. 5D).
Discussion
Resistance of bacterial pathogens to common antibiotics
in considered a global threat and the majority of recent
advances in antibiotic discovery have focused on Gram-
positive targeting drugs (Ling et al., 2015; Zipperer
et al., 2016). AV therapy offers a promising alternative
to more traditional antibiotic treatment (Rasko and Sper-
andio, 2010; Allen et al., 2014). Such an approach, how-
ever, requires a detailed understanding of the
mechanisms behind an AV route to increase the focus
on targeting virulence mechanisms specifically. Given its
widespread nature and essential role in the pathogene-
sis but not survival of many Gram-negative pathogens,
the T3SS offers an attractive target for the development
of novel AV therapies (Keyser et al., 2008).
Colonization of both humans and cattle by EHEC is
highly dependent on the T3SS, encoded on the LEE
pathogenicity island. Therefore, compounds that inter-
fere with the expression and function of the T3SS offer
an attractive proposition to combat this disease. Previ-
ous work had demonstrated that the SA class of com-
pounds was capable of reducing expression of the
T3SS. However, studies into their mechanism of action
revealed multiple target proteins, many of which were
associated with bacterial metabolic processes.
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Studies have used statistical molecular design to
expand the library of SA class inhibitors (Dahlgren
et al., 2010). In this work we wanted to replace the
imine core with by the introduction of hydrazine-
containing heterocycles that would offer greater stabil-
ity. Two different hydrazine-containing rings were
selected: the 1,4,5,6-tetrahydro pyridazine (THP) and
the 1,2-dihydrophthalazine (DHP). The THP core
includes two nitrogens in a six-membered ring with a
half-chair conformation. In contrast, the DHP core has
a completely planar conformation and the ortho-fused
phenyl ring gives a much greater hindrance in the cen-
tral core of the molecule than the THP scaffold, also
increasing the lipophilicity of the compound. To further
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expand the series, it was decided to replace the car-
bonyl function with a sulfone group, creating further
derivatives for testing.
One key advantage of AV compounds compared with
traditional antibiotics is the reduced selective pressure
for the development of resistance. To this end, we dem-
onstrate here that the new series of compounds do not
inhibit the growth or viability of EHEC even at 200 lM,
the highest concentration tested. However, only two of
the new series were active at reducing secretion of
known LEE encoded effector proteins. Both RCZ12 and
RCZ20 resulted in the accumulation of EspD in the bac-
terial cytoplasm suggesting they might act by interfering
with the normal secretion of this protein. Biotinylated
derivatives of RCZ12/20 were used to help identify
potential binding partners. Remarkably, we reproducibly
identified EspD as a potential target of both lead com-
pounds. While it would be desirable to show a direct,
physical, interaction of RCZ12/20 with EspD this has
proven problematic. EspD is produced in the bacterial
cytoplasm and interacts with at least two chaperones,
CesD and CesD2. Both appear important for the stability
and secretion competence of EspD. Chatterjee et al.
successfully purified recombinant EspD (Chatterjee
et al., 2015) and kindly donated samples for testing but
high concentrations of urea (8 M) and detergents had to
be used to dissolve the protein making subsequent bio-
physical studies difficult to perform. For this reason we
used a genetic approach to demonstrate that removal of
the EspD coiled-coil domain 1, previously shown to be
important for T3SS mediated host cell binding, com-
pletely reverses the inhibitory effects of RCZ12, strongly
supporting the notion that this is the site of compound
binding to EspD. Physical interference with the transloca-
tion process can explain how we observe both an inhibi-
tion of secretion and cytoplasmic accumulation of EspD.
Intriguingly, our data suggest that RCZ12/20 do not
work solely through binding to EspD. It was observed
that while EspD accumulates intracellularly after RCZ12/
20 treatment, this is not the case for Tir, which was both
blocked for secretion and down-regulated in its transcrip-
tion. These data suggest some feedback to other mem-
bers of the LEE through EspD blocking. The
transcriptional down-regulation observed by RNA-seq
showed that all 41 ORFs of the LEE were significantly
repressed after RCZ20 treatment. Indeed, previous stud-
ies on the SA class of inhibitor compounds have demon-
strated transcriptional down-regulation of virulence
factors, including the LEE T3SS. Further analysis of this
associated transcriptional regulation using GFP-reporters
revealed that deletion of espD did not affect LEE1 tran-
scription despite its essential role in T3SS function and
A/E lesion formation. Treatment with RCZ12, however,
resulted in significant LEE1 down-regulation, similarly to
RCZ20 by RNA-seq. This suggests a dual functionality
of these inhibitors: physical binding to EspD and disrupt-
ing its efficient translocation through the T3SS and tran-
scriptional down-regulation of the LEE by an undefined
mechanism. However, we maintain that the primary and
most effective mechanism of T3SS inhibition by RCZ12/
20 is EspD interaction. This is supported by the finding
that EspD-HAD138–171 is still capable of being secreted
after treatment with RCZ12/20 and despite mild down-
regulation of LEE transcription. Hence, the down-
regulation of the LEE by RCZ12/20 is not sufficient to
explain the major phenotype, a distinct lack of effector
protein secretion. Given the essential nature of translo-
cation pore formation and establishment of host cell
binding, along with the known hierarchy of T3SS effector
translocation, this strategy of AV therapy is a viable
option for therapeutic treatment of EHEC infections.
Given that the T3SS is central to the pathogenesis of
a wide range of Gram negative bacteria, it would be
interesting to test any effects of RCZ12/20 on related
organisms. Both enteropathogenic E. coli (EPEC) and
C. rodentium carry direct homologs of EspD.
Fig. 5. Characterization of the affects of RCZ20 treatment on transcriptional regulation of type 3 secretion in EHEC.
A. RNA-seq results of EHEC cultured in MEM-HEPES with and without RCZ20. A gene was determined as differentially expressed if it
displayed significant upregulation or downregulation with an FDR corrected p value of< 0.05. Three independent biological replicates were
used in RNA-seq experiments.
B. Expanded view of the LEE island transcriptional landscape in response to RCZ20 treatment. The heatmap indicates the expression pattern
(log2 normalized reads mapped) of each ORF within the LEE for each replicate. A schematic map of the LEE operon structure as well as
master regulation by Ler is indicated above.
C. Validation of RNA-seq data using promoter-GFP reporter fusions. Cell cultures carrying reporter fusion plasmids prpsM:GFP (housekeeping
gene expression) and pLEE1:GFP (LEE expression) were assayed under identical conditions to those performed in the RNA-seq experiment
for treatment with both RCZ12 and RCZ20 (50 and 200 lM). Promoter expression was measured as relative fluorescence units (RFU) and
were normalized to OD600 0.6. The expression level of either rpsM or LEE1 in the WT background is indicated by the red dotted line. As a
comparator, prpsM:GFP and pLEE1:GFP activity were also measure in response to ME0055.
D. RCZ12/20 compound activity exhibits dual functionality. pLEE1:GFP activity was measured in both the EspD-HA and EspD-HAD138–171
genetic backgrounds to investigate if the transcriptional effects exhibited by compound treatment are due to feedback from EspD inhibition.
GFP reporter assays were performed in biological triplicate and are displayed as mean and standard error.
E. Summary of RCZ12/20 dual-functionality as AV compounds – primarily inhibition of EspD function by direct binding and mild transcriptional
downregulation of the LEE with minimal off-target effects.
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Interestingly, comparison of the EspD proteins from
EHEC (EHEC str. Sakai), EPEC (O126:H6 str. E2348/
69) and C. rodentium (str. ICC168) reveals several
amino acid substitutions within the coiled-coiled domain
we propose to be a key target of RCZ12. The patho-
gens Salmonella typhimurium, Shigella dysenteriae and
Yersinia Pesudotuberculosis also use pore-forming
effectors with similarity to EspD. However, despite shar-
ing a conserved function, they are quite distinct to EspD
with less than 27% protein identity. Therefore, extensive
additional testing would be required to examine if
RCZ12/20 are capable of affecting these other patho-
gens. Taken together, our study provides a comprehen-
sive analysis of a new class of effective and highly
selective T3SS inhibitors that should provide a baseline
for future research and improvements.
Experimental procedures
Bacterial strains, plasmids and growth conditions
Strains and plasmids used in this study are listed in Sup-
porting Information Tables S1 and S2 respectively. Gener-
ation of single gene deletion strains was carried out using
the Lambda Red mediated recombination method, as
described by Datsenko and Wanner (Datsenko and Wan-
ner, 2000). Allelic exchange plasmids for generation of
the truncated-EspD-HA strains (see below) were made
using the NEBuilder HiFi DNA Assembly Cloning Kit (New
England Biolabs) according to the manufacturer specifica-
tions and all the clones were confirmed by sequencing.
Oligonucleotide primers (Invitrogen) are listed in Support-
ing Information Table S3. Bacterial strains were isolated
from pure culture agar plates and used to inoculate liquid
media. 5 ml overnight cultures were diluted to an optical
density (OD600) of 0.05 in LB, M9 or MEM-HEPES for
induction of type 3 secretion (SigmaVR M7278) supple-
mented with standard concentrations of antibiotics when
required.
Synthesis of chemical compounds
The synthesis, modification and purification of the com-
pounds used in this study are detailed in the Supporting
Information Materials and Methods. Compounds were dis-
solved in DMSO with the final DMSO concentration kept
below 2% for all assays.
Compound stability analyses
The stability of the compounds in acidic conditions was
assessed using 1H NMR. Briefly, 15 mg of compounds
were dissolved in DMSO-d6 containing 20% hydrochloric
acid (DCl) and DMSO-d6 alone. 1H-NMR spectra were
recorded at 500 MHz using a Bruker Avancell 500 instru-
ment. Samples were analyzed at t5 0 h, 2 h and 12 h after
incubation.
Analysis of compound uptake by targeted
metabolomic profiling
Bacteria were grown in M9 minimal medium to an optical
density of 0.9 and incubated with RCZ12 or RCZ20 for 60
min. Fractions were separated by centrifugation (2 min at
15 000 g). Bacterial pellets and supernatants were inde-
pendently treated with a 1:1:3 chloroform/water/methanol
solution and the resulting supernatants were analyzed by
hydrophilic interaction liquid chromatography (HILIC) to
measure their relative concentrations in each respective
background. HILIC analysis was performed at the University
of Glasgow Polyomics facility. Briefly, compounds were sep-
arated using a 15 cm 3 4.6 mm ZIC-pHILIC column (Merck
Sequant) running at 300 uL/min. Mobile phase was A:
100% H2O with 20 mM ammonium carbonate and B: 100%
Acetonitrile. Separation was performed on an UltiMate 3000
RSLC (Thermo) with a gradient running from 20% A, 80%
B to 80% A, 20% B in 15 min, followed by a wash at 5% B
for 3 min and equilibration at 20%A for 6 min for a total run-
time of 24 min. Detection was performed using a Q-
Exactive (Thermo) at 70 000 resolution in positive/negative
switching mode.
Generation of HA-tagged EspD and EspD truncates
Engineered EspD-HA mutant strains were generated using
allelic exchange, optimized for EHEC according to the pro-
tocol by Emmerson et al. (Emmerson et al., 2006). The
method relies on the creation of temperature sensitive
exchange plasmids containing homologous flanking regions
that mediate insertion of the gene of interest through
homologous recombination into the bacterial chromosome
at their original location. Exchange plasmids for this pro-
cess comprised of pIB307-LEE4-SacB/Kan (to generate the
intermediate strain with the SacB/Kan cassette on the chro-
mosome in place of espD) and pIB307-LEE4-EspD-HA (to
allow the incorporation of the HA epitope onto the coding
frame of EspD in replacement of the SacB/Kan cassette).
The plasmids only replicate at the permissible temperature
of 288C and are selectable on chloramphenicol. The initial
recombination of SacB/Kan occurs at 428C and is selectable
on Kanamycin. The second and final recombination of the
modified EspD epitope is negatively selected for with sucrose.
Subsequently, pIB307-LEE4-EspD-HAD26–81, pIB307-LEE4-
EspD-HAD138–171, pIB307-LEE4-EspD-HAD176–251 and pIB307-
LEE4-EspD-HAD333–356 were created to allow the generation
of 5 chromosomally encoded EspD-HA truncates, each
lacking the series of amino acids specified in the name of
the plasmid.
Affinity chromatography using biotin-labeled RCZ12
and RCZ20
The pull-down assay was performed using streptavidin-
coated magnetic beads (DynabeadsTM M-280 Streptavidin
from InvitrogenVR ). EHEC strain TUV93–0 was cultured at
378C to an OD600 of 0.9. The cells were pelleted by cen-
trifugation, washed several times with PBS and concen-
trated in PBS to a final volume of 2 ml. The suspended
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cells were lysed by sonication and kept under ice. The
magnetic beads were aliquoted and washed with PBS using
a magnetic rack. A 250 lM solution of Biotin-RCZs in
PBS:DMSO (10:1) was added to the beads and incubated
shaking for 1 h at room temperature. The Biotin-compound
solution was removed and the beads were washed three
times with PBS. 500 ll of the suspended cell lysate solution
was then added to the tubes and incubated with shaking
for another hour at room temperature. The lysate solution
was removed and the beads were washed three times with
PBS. Once washed, 15 ll of SDS sample buffer (Invitrogen,
UK) was added to the tube and the beads were boiled at
958C for 10 min to promote specific bound protein denatu-
ration. Equals volumes of PBS washes and SDS samples
were loaded onto a 4–12% Bis-Tris gel, the proteins were
separated through SDS-PAGE electrophoresis and visual-
ized by Coomassie Blue staining (Novex SDS-PAGE sys-
tem, Invitrogen). Specific bound proteins were excised for
subsequent in-gel digestion and analysis by tandem mass-
spectrometry. Proteins analyzed by peptide mass finger-
printing were given a MOWSE score to indicate the proba-
bility of the identification being correct. We set a threshold
MOWSE value of 100 or greater, ensuring a significance of
p< 1028.
Analysis of total secreted protein
Strains were cultured in prewarmed MEM-HEPES with the
desired compound concentration. Cultures were grown at
378C to an OD600 0.7 and then the solution was centri-
fuged for 10 min at 3750 rpm and 48C to separate the cells
from the supernatant. The cell pellets were lysed using
BugBuster Protein Extraction buffer (Merck, New Jersey,
USA), while the supernatant solution was treated with 10%
(v/v) TCA at 48C overnight. Secreted proteins were then
centrifuged for 1 h at 3750 rpm, 48C and re-suspended in
Tris-HCl solution (pH 8.0). An equal amount of bovine
serum albumin (BSA) was added to each secreted protein
sample fraction to confirm equal loading of total secreted
protein. Proteins from both whole cell and secreted frac-
tions were analyzed by Western blot using the Novex sys-
tem (Invitrogen) with primary antibodies EspD (1/5000), Tir
(1/1000) or GroEL (1/10 000) and protein levels were com-
pared by densitometry using ImageJ. Experiments were
performed a minimum of three times to confirm the results.
In vitro GFP reporter fusion assays
In vitro transcription assays were carried out using a series
of reporter plasmids containing the promoter region of inter-
est fusion in-frame to eGFP, which were previously gener-
ated (Roe et al., 2003). Transformed strains were cultured
in MEM-HEPES at 378C with shaking at 200 rpm. Hourly
samples were extracted for measurement of optical density
(growth) and fluorescence (relative promoter activity). GFP
expression was measured in a black 96-well plate (excita-
tion at 485 nm; emission at 550 nm) using a FLUOstar
Optima Fluorescence Plate Reader (BMG Labtech, UK).
The plasmid pAJR70 containing the promoterless eGFP
fusion was used as a negative control for background
fluorescence. GraphPad Prism 5.0 (San Diego, CA, USA)
was used to both plot and analyze the data. Experiments
presented are the mean (6SEM) of three biological
replicates.
Transmission electron microscopy
Bacterial samples were fixed on ice with 1% paraformalde-
hyde/PBS for an hour and washed three times in PBS for 5
min each time. Sample suspension droplets (5 ll) were
placed onto Formvar/Carbon nickel-coated support grids,
which had been pretreated with a 0.1% poly-L-lysine solu-
tion. Bacterial suspensions were left to settle for 20 min, the
grids were floated sample on 0.05 M glycine/PBS droplets
for 5 min and then rinsed three times with 3% BSA/PBS for
5 min. Bacterial samples were placed onto an a-EspA
(1:100 dilution) for an hour, washed six times on 3% BSA/
PBS for 5 min each and then placed onto droplets of sec-
ondary GAR 10 nm gold for an hour. Samples were washed
six times in 3% BSA/PBS for 5 min each, rinsed with PBS
six times for 3 min, fixed on 1% glutaraldehyde/PBS for 5
min, washed six times in distilled water and then left to dry.
Immunostained bacterial samples were viewed on a FEI Tec-
nai T20 TEM running at 200 kV and dm4/tiff images were
captured using Gatan Digital Imaging software.
Total RNA extraction and mRNA enrichment
Bacteria were cultured as described above in MEM-HEPES
before being mixed with two volumes of RNAprotect rea-
gent (Qiagen, Valencia, CA, USA), incubated for 5 min at
room temperature and harvested by centrifugation. Three
biological replicates were used for each condition of the
transcriptome analysis. Total RNA was extracted using an
RNeasy kit (Qiagen) according to the manufacturers’ speci-
fications. Genomic DNA was removed using TURBO
DNase (Ambion, Carlsbad, CA, USA). Total RNA samples
were enriched for mRNA using a MICROBexpress mRNA
enrichment kit (Ambion). Integrity of enriched mRNA sam-
ples for sequencing were tested using an Agilent Bioana-
lyzer 2100 at the University of Glasgow Polyomics Facility.
RNA-sequencing and transcriptome analysis
cDNA synthesis, library generation and Illumina sequencing
was performed at the Edinburgh Genomics facility on the
Illumina HiSeq 2500 platform obtaining 100 bp single end
reads. Samples of TUV 93–0 cultured in MEM-HEPES with
and without 50 lM RCZ20 were used to extract mRNA.
Raw sequencing reads were assessed for quality using
FastQC (Babraham Bioinformatics, Cambridge, UK) and
trimmed where necessary using CLC Genomics Workbench
(CLC Bio, Aarhus, Denmark). Sequence reads were then
mapped to the EDL933 reference genome (NCBI
NC_002655.2) allowing for 3 mismatches per read and at
least 5 reads per open reading frame under all conditions
tested. To determine differential expression between condi-
tions, analysis was performed using the Empirical analysis
of DGE tool in CLC Genomics Workbench, which
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implements the EdgeR Bioconductor tool (Robinson et al.,
2010). Differentially expressed genes were identified by
positive or negative absolute fold change and considered
significant if the corrected p-value was0.05 (false-discov-
ery rate of 5%). Differentially expressed genes (DEGs)
were grouped by biological function according to their des-
ignated gene ontology (GO) terms obtained from the
EMBL-EBI QuickGO database (https://www.ebi.ac.uk/
QuickGO/). Bar charts summarizing the data were gener-
ated in GraphPad Prism version 5.0 (San Diego, CA, USA)
and heatmaps of gene expression patterns were generated
in Microsoft Excel. The raw sequence reads in this article
have been deposited in the European Nucleotide Archive
under the identifiers PRJEB17972 (treated with RCZ20)
and the previous data set PRJEB12065 used as the
untreated control for comparative purposes.
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